Mohamed bouattour

List of Publications by Year
in descending order

57	3,391	331670 21	182427 51
papers	citations	h-index	g-index

59	59	59	4675
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. British Journal of Surgery, 2022, 109, 455-463.	0.3	7
2	Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review. European Journal of Clinical Pharmacology, 2022, , 1.	1.9	3
3	Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers, 2022, 14, 2634.	3.7	0
4	Outcome of liver cancer patients with SARSâ€CoVâ€2 infection: An International, Multicentre, Cohort Study. Liver International, 2022, 42, 1891-1901.	3.9	11
5	Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101491.	1.5	18
6	Computed Tomography-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 405-416.	1.5	10
7	Healthâ€related qualityâ€ofâ€life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTEâ€240. Cancer, 2021, 127, 865-874.	4.1	20
8	Transarterial chemoembolisation enhances programmed deathâ€1 and programmed deathâ€ligand 1 expression in hepatocellular carcinoma. Histopathology, 2021, 79, 36-46.	2.9	49
9	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101590.	1.5	17
10	Nurse coordinator roles in the management of patients with hepatocellular carcinoma: A French national survey. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101650.	1.5	3
11	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. Clinical Therapeutics, 2021, 43, 1201-1212.	2.5	4
12	Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101731.	1.5	2
13	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	4.9	36
14	Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent. Diagnostic and Interventional Imaging, 2021, 102, 735-742.	3.2	13
15	Long-term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas. JHEP Reports, 2021, 3, 100326.	4.9	7
16	Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). European Journal of Cancer, 2021, 154, 46-56.	2.8	10
17	Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS. JHEP Reports, 2021, 3, 100380.	4.9	29
18	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 2020, 38, 193-202.	1.6	1,255

#	Article	IF	Citations
19	Biological response under treatment and prognostic value of protein induced by vitamin K absence or antagonist-II in a French cohort of patients with hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2020, 32, 1364-1372.	1.6	8
20	PARP inhibition in treatment of pancreatic cancer. Expert Review of Anticancer Therapy, 2020, 20, 939-945.	2.4	14
21	ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma. Clinical Cancer Research, 2019, 25, 5859-5865.	7.0	64
22	Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellularâ€cholangiocarcinoma. Liver International, 2019, 39, 2386-2396.	3.9	32
23	Systemic Treatment for Advanced Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 341-358.	7.7	82
24	Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clinical Pharmacokinetics, 2019, 58, 983-1014.	3.5	17
25	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 454-465.	8.1	36
26	Management of immune-related adverse events resulting from immune checkpoint blockade. Expert Review of Anticancer Therapy, 2019, 19, 209-222.	2.4	20
27	Macrotrabecularâ€massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology, 2018, 68, 103-112.	7.3	159
28	Recent developments of câ€Met as a therapeutic target in hepatocellular carcinoma. Hepatology, 2018, 67, 1132-1149.	7.3	190
29	Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?â€"review of the open label phase III trial CONKO 005. Hepatobiliary Surgery and Nutrition, 2018, 7, 399-402.	1.5	0
30	Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?. Journal of Hepatology, 2018, 69, 548-550.	3.7	71
31	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2017, 18, 1624-1636.	10.7	595
32	Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. ESMO Open, 2017, 2, e000238.	4.5	37
33	Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. International Journal of Nanomedicine, 2016, Volume 11, 6207-6216.	6.7	23
34	Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. Trials, 2016, 17, 563.	1.6	4
35	Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlo	1.0	14
36	Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World Journal of Hepatology, 2015, 7, 910.	2.0	6

#	Article	IF	Citations
37	Atypical Presentation of Hepatocellular Carcinoma Mimicking a Gastric Hepatoid Adenocarcinoma. Medicine (United States), 2015, 94, e1101.	1.0	3
38	Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?. Journal of Clinical Oncology, 2015, 33, 2484-2485.	1.6	6
39	Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World Journal of Hepatology, 2015, 7, 2245.	2.0	8
40	Abstract 221: Ex vivo cultures of freshly explanted tumors: a potent translational approach for screening novel targeted agents. , 2015, , .		0
41	Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified) Tj ETQq1 1 0.784314 rgBT /Overlo Hepatocellular Carcinoma Treated With Sorafenib. Oncologist, 2014, 19, 394-402.	3.7	134
42	Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Investigational New Drugs, 2014, 32, 1028-1035.	2.6	21
43	The Sorafenib for Hepatocellular Carcinoma (HCC) in Adjuvant Setting: The End of the Story was Already Written?. Gastroenterology & Hepatology (Bartlesville, Okla), 2014, 1, .	0.1	0
44	Abstract 3484: Ex-vivo cultures of freshly explanted tumor specimens (TIPCANÂ®), a potent translational approach for screening novel targeted agents. , 2014, , .		0
45	Intratumoral Gas in Hepatocellular Carcinoma following Transarterial Chemoembolization: Associated Factors and Clinical Impact. Journal of Vascular and Interventional Radiology, 2013, 24, 1623-1631.	0.5	9
46	Abstract C268: MET-inhibition using SU11274 and HER-inhibitions with lapatinib impair proliferation, motility and invasion in hepatocellular carcinoma (HCC) and exhibits an increased efficacy un sorafenib-tolerant model.. , 2013, , .		0
47	Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus. Pancreatology, 2012, 12, 516-517.	1.1	3
48	Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Targeted Oncology, 2012, 7, 127-133.	3.6	45
49	Blinded independent central response assessment using RECIST, mRECIST, and CHOI criteria in patients treated with sorafenib for advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2012, 30, 172-172.	1.6	1
50	Enjeux et spÃ©cificitÃ©s de lâ€™Ã©valuation radiologique des tumeurs neuroendocrines pancrÃ©atiques traitÃ©es par les thÃ©rapies ciblÃ©es. CancÃ©ro Digest, 2012, , .	0.0	0
51	Prospective evaluation of the management of hepatocellular carcinoma in the elderly. Digestive and Liver Disease, 2011, 43, 1001-1005.	0.9	22
52	Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. Journal of Hepatology, 2011, 54, 1073-1078.	3.7	50
53	Novel molecular therapies in hepatocellular carcinoma. Liver International, 2011, 31, 151-160.	3.9	38
54	Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib. Clinical Cancer Research, 2011, 17, 4504-4512.	7.0	83

#	Article	IF	Citations
55	Abstract B175: TGF-Î²-RI kinase inhibitors LY2157299 and LY364947 decrease motility and invasion in hepatocarcinoma (HCC) cells developing resistance to VEGFR/PDGFR kinase inhibitors.. Molecular Cancer Therapeutics, 2011, 10, B175-B175.	4.1	1
56	Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology and Hepatology, 2010, 22, 1106-1110.	1.6	65
57	Sunitinib in Hepatocellular Carcinoma: Redefining Appropriate Dosing, Schedule, and Activity End Points. Journal of Clinical Oncology, 2009, 27, e248-e250.	1.6	33